Research

Hormonal

Tirzepatide 15 mg administered once weekly for 72 weeks is the most cost-efficient intervention for achieving high-magnitude weight loss targets (15% and 20%) in adults with obesity, yielding a cost per kilogram of weight loss of £89.24.

For adults with obesity seeking significant weight loss, the 15mg weekly dose of tirzepatide, combined with diet and exercise, offers the best value for achieving major weight reduction goals (15-20%) over 72 weeks, despite higher initial drug costs, due to superior efficacy and potential long-term healthcare savings.

GoodSupportsHIGH confidence
The 15 mg dose was the most cost-efficient for achieving higher weight loss targets (15% and 20%). Cost/kilogram of weight loss at 72W was £102.86, £85.41, and £89.24 for 5, 10, and 15 mg, respectively.
Marc Evans et al. · Advances in Therapy · 2025

Why this rating

Based on a large, randomized, double-blind, placebo-controlled trial (SURMOUNT-1, N=2539), though the analysis focuses on cost rather than clinical efficacy endpoints directly.

Source

Analysis of Tirzepatide Acquisition Costs and Weight Reduction Outcomes in the United Kingdom: Insights from the SURMOUNT-1 Study

Marc Evans et al. · Advances in Therapy · 2025

DOI 10.1007/s12325-025-03194-8

rct · n=2539Cited 5×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →